How Lumoxiti Targets Hairy Cell Leukemia Cells
Lumoxiti (moxetumomab pasudotox-tdfk) is an intravenous CD22-directed cytotoxin approved by the FDA for relapsed or refractory hairy cell leukemia (HCL) in adults who received at least two prior systemic therapies.[1] It treats HCL by binding to CD22, a protein overexpressed on the surface of malignant B-cells characteristic of this rare blood cancer.
Once bound, Lumoxiti internalizes into the cancer cell via receptor-mediated endocytosis. Inside, the fused Pseudomonas exotoxin A (PE38) component ADP-ribosylates elongation factor 2 (EF-2), halting protein synthesis and triggering cell death through apoptosis.[1][2] This mechanism selectively kills CD22-positive HCL cells while sparing most normal cells, which express little CD22.
Clinical trials showed 75% overall response rates, with 36% complete remissions in heavily pretreated patients.[1]
What Happens During a Treatment Cycle
Lumoxiti is given in 28-day cycles for up to six cycles. Patients receive 0.04 mg/kg on day 1, 0.16 mg/kg on days 8 and 15, premedicated with acetaminophen, antihistamines, and corticosteroids to reduce infusion reactions and capillary leak syndrome.[1] Cycles repeat if response improves or stable disease persists. Retreatment is possible after 16 weeks off therapy if relapse occurs.
Common Side Effects and Management
Capillary leak syndrome affects most patients (e.g., hypoalbuminemia, edema), managed by holding doses if albumin drops below 3.0 g/dL and volume control.[1] Other issues include nausea, fatigue, headache, and infections from neutropenia. Hemolytic uremic syndrome occurs rarely (2-5%). Monitoring includes weekly labs for electrolytes, renal function, and albumin.
How Effective Is It Compared to Prior Therapies?
In the phase 3 PITON trial, Lumoxiti achieved higher durable response rates than prior standards like cladribine rechallenge (median progression-free survival not reached at 16 months).[2] It fills a gap for multi-relapsed HCL, where options dwindle.
Who Makes Lumoxiti and What's Its Patent Status?
AstraZeneca markets Lumoxiti, launched in 2018. U.S. patents cover the composition and methods until around 2031-2033, per DrugPatentWatch.com.[3] No generics or biosimilars are approved yet.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761032s000lbl.pdf
[2] Lancet Oncology (PITON trial): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30791-5/fulltext
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/LUMOXITI